Citations

Clear

479 citation(s) found for "Tobias, JS".

1659: A DEEP LEARNING APPROACH FOR ULTRASOUND-BASED IDENTIFICATION OF PNEUMOTHORAX IN TRAUMATIC INJURY
Navarro, Sergio, Özbilen, Ege, Thorn, Michael, Williams, Alec, Chaar, Mohammed Abou, Stephens, Daniel, Navarro, Sergio M. , Williams, Alec, Kummer, Tobias , Stephens, Daniel

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001188632.48186.54 Get It

Gene Portals: A Framework for Integrating Clinical, Functional, and Structural Evidence into Rare Disease Variant Classification
Brünger, Tobias , Krey, Ilona , Kim, Suyeon, Klöckner, Chiara , Myers, Scott J, Johannesen, Katrine M. , Stefanski, Arthur , Taylor, Gary, Macnee, Marie , Dahl, Rebekka S., Yuan, Hongjie, Kim, Sukhan, Helbig, Ingo, Pan, Jen, Kurganov, Erkin , Baez, David, Zuberi, Sameer M., Lerche, Holger, May, Patrick, Ivaniuk, Alina, Meskis, Mary Anne , Hood, Veronica , Schust, Leah F., Freed, Amber, Froelich, Steven, Deng, Alexander T., Bouman, Arjan , Hajianpour, M.J. , Pal, Deb K. , Danvoye, Leslie, Lederer, Damien , BALCI, TUĞÇE, Hagebeuk, Eveline , Heidlebaugh, Alexis R. , Oetjens, Kathryn F., Striano, Pasquale, Williams, Sarah Drewes, Engelen, Kalene van , Howell, Katherine B. , Khoury, Jean , Benke, Tim A., Strehlow, Vincent , Platzer, Konrad, Ramsey, Amy J, Manaster, Lisa, Malepati, Sunitha, Fox, Pangkong M., Noebels, Jeffrey, Chung, Wendy, Poduri, Annapurna, Stripe, Laina Lusk, Ruggiero, Sarah M., Cohen, Stacey, Wilmarth, Olivia, Prentice, Anna Jenne, Cha, Esther, Budnik, Nikita , Kramer, Audra A. , Gh, Zhang, Palotie, Aarno, Daly, Mark J., Møller, R., Lemke, Johannes R., Lal, Dennis , Møller, Rikke S. , May, Patrick , Bruenger, Tobias , Pan, Jen Q , Farrant, Mark , Wyllie, David J A , Bosselmann, Christian , Mantegazza, Massimo , May, Patrick , Ivaniuk, Alina , Goodspeed, Kimberly , Trinidad, Marena , Aledo-Serrano, Ángel , Pal, Deb K , Platzer, Konrad , Ruggiero, Sarah M , Daly, Mark J. , George, Alfred L , Brunklaus, Andreas , Møller, Rikke S , Myers, Scott J. , Taylor, Gary, Pérez‐Palma, Eduardo , Schorge, Stéphanie , Dahl, Rebekka S. , Perszyk, Riley E. , Bajaj, Sunanjay , Helbig, Ingo , Wollmuth, Lonnie P. , Báez-Nieto, David , Zuberi, Sameer M. , Boßelmann, Christian M. , Mantegazza, Massimo , Cestèle, Sandrine , Ivaniuk, Alina , Kang, Jing‐Qiong , Gati, Cornelius , Montanucci, Ludovica , Wüster, Arthur , Deng, Alexander T. , Borovikov, Artem O. , Sharkov, Artem A. , Bouman, Arjan , Hoffman, Trevor L. , Howell, Katherine B. , Benke, Tim A. , Platzer, Konrad , Ramsey, Amy J. , Fox, Pangkong , Noebels, Jeffrey L. , Chung, Wendy K. , Poduri, Annapurna , Lusk, Laina G. , Cohen, Stacey , Smith, Lacey A. , Boesch, Sylvia , Prentice, Anna Jenne , Hommersom, Marina P. , Vanoye, Carlos G. , Nothnagel, Michael , Palotie, Aarno V. , George, Alfred L. , Zárate, Yuri A. , Brunklaus, Andreas , Traynelis, Stephen F. , Lemke, Johannes R.

Mayo Clinic

No container title available | March 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.05.26347086 | PMID 41822692 Get It

Abstract Rare Mendelian disorders affect 300-400 million people globally. Although genetic testing has become widely adopted, gene-specific evidence for tailored variant interpretation remains scattered across resources. We present Gene Portals, a framework for gene-centered multimodal knowledge bases that co-localize expert-harmonized clinical data, functional assays, population variation, structural annotations and gene-specific ACMG/AMP specifications within a single resource. A modular interface integrates this unified evidence with VCEP-refined ACMG specifications to enable automated gene-specific variant classification, infer molecular mechanisms, and support cross-gene analyses. We demonstrate the framework’s utility across five Gene portals spanning eleven neurodevelopmental disorder-associated genes, integrating data from 4,423 individuals with 2,838 unique variants, 36,149 ClinVar submissions, and 1,044 expert-curated molecular readouts. By organizing evidence that is otherwise dispersed across multiple sources into a unified, queryable framework, the SCN, GRIN, CACNA1A, SATB2 and SLC6A1 Gene Portals became widely used community resources and provide an extensible template for standardized rare-disease variant interpretation and mechanism-aware discovery.
Quality of life and care experiences in a US multi-institutional neuroendocrine tumor cohort
O’Rorke, Michael A, DeCook, Rhonda, McDowell, Bradley D. , Gryzlak, Brian , Rudzianski, Nicholas J, Serrano, Kimberly , Wehrheim, Abigayle M., Grewal, Udhayvir Singh , Halfdanarson, Thorvardur R, Gamblin, T Clark, Cowell, Lindsay G, Else, Tobias , Chandaka, Sravani , He, Fiona , Geller, David, Ramirez, Robert A, Lancaster, W. M., Mailman, Josh A, Moran, Heather, Wahmann, Maryann, Gellerman, Elyse, Chrischilles, E., Investigators, The NET-PRO Study, Chamberlain, Alanna M, Cerda, Vanessa, Early, Carol, Hamilton, Harley C, Indrees, Kamran, Lewis-Hughes, A., O’Dell, Angela L, Roller, Lance, Taylor, Bradley W, Tepper, Mia S, Wahmann, Maryann, West, Kristin M, Zamba, Gideon K D, O’Rorke, Michael A. , Xu, Tao , McDowell, Bradley D , Gryzlak, Brian M , Rudzianski, Nicholas J , Serrano, Kimberly C , Grewal, Udhayvir S , Dillon, Joseph S , Halfdanarson, Thorvardur R , Else, Tobias , Soares, Heloisa P , Sukrithan, Vineeth , Sanoff, Hanna , He, Fiona C , Ramirez, Robert A , Liu, Mei , Mailman, Josh , Moran, Heather , Wahmann, Maryann , Gellerman, Elyse , Chrischilles, Elizabeth A , Xu, Tao , Chandrasekharan, Chandrikha , Dillon, Joseph S. , Hálfdánarson, Þorvarður R. , Gamblin, T. Clark , Cowell, PhD Lindsay G., Soares, Heloisa P. , Sukrithan, Vineeth , Sanoff, Hanna K. , Liu, Mei , Lancaster, William, Mailman, Josh , Chamberlain, Alanna M. , Hourcade, Juan Pablo , Kazmi, Syed Mohammad Ali , Lancaster, William, Ramnaraign, Brian Hemendra , Taylor, Bradley , West, Kristin M, Zamba, Gideon K D

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 3, 2026 | Volume: 118 | Issue: 8 | Pages: 1403-1415

10.1093/jnci/djag069 | PMID 41808486 Get It

Abstract Background Neuroendocrine tumors (NETs) are rare, heterogeneous neoplasms associated with prolonged survival and substantial symptom burden. However, patient-reported outcomes across NET subtypes remain poorly characterized, particularly in real-world settings. This study describes baseline health-related quality of life (HRQoL) and care experiences among patients with gastroenteropancreatic and lung NETs, examining differences by tumor site and time since diagnosis. Methods The Neuroendocrine Tumors–Patient Reported Outcomes study is a prospective, multi-institutional US cohort of adults (aged 18 years and older) with incident small intestinal, pancreatic, gastroenteropancreatic, or lung NETs diagnosed from January 2018 through September 2024, identified via a validated electronic medical record–based computable phenotype. Baseline surveys assessed HRQoL, symptoms, care experiences, and clinical characteristics using validated instruments. Descriptive statistics and standardized mean differences compared responses by NET site and time since diagnosis. Results Among 2367 participants (mean age = 57.8 years; 57.3% female), 1974 had gastroenteropancreatic NETs (659 small intestinal NET, 555 pancreatic NET) and 393 had lung NETs. Fatigue (mean = 33.0), insomnia (mean = 32.5), and diarrhea (mean = 25.7) were the most burdensome symptoms. Lung NET patients reported worse dyspnea (standardized mean difference = 0.58, P < .001) and lower physical, role, and global QoL scores than those with gastroenteropancreatic NETs, while pancreatic NET patients reported better functioning. Diarrhea worsened over time, especially in small intestinal NETs. Most rated care highly (75.3%) but cited concerns about treatment side effects (80.4%), costs (60.7%), and travel burden (58.8%). Conclusions This large US cohort reveals persistent symptom burden and HRQoL variation by tumor site and disease duration, underscoring the need for longitudinal HRQoL assessment in NET care.
Using a participation monitoring database to enhance recruitment in a rare cancer population
O’Rorke, Michael A. , Gryzlak, Brian , Xu, Tao, DeCook, Rhonda, Rudzianski, Nicholas J., Serrano, Kimberly , Wehrheim, Abigayle M., Schnell, Michael J., Witter, Carrie L., Gamblin, T. Clark , Kazmi, Syed Sohail, Cowell, Lindsay G., Else, Tobias, Chandaka, Sravani , Sanoff, Hanna K. , He, Fiona , Ramirez, Robert A., Liu, Mei, Lancaster, William, Mailman, Josh , Moran, Heather, Wahmann, Maryann, Gellerman, Elyse, Chrischilles, Elizabeth A., Liu, Mei , Sanoff, Hanna , O’Rorke, Michael , McDowell, Bradley D. , Rudzianski, Nicholas J , Serrano, Kimberly C., Grewal, Udhayvir Singh , Chandrasekharan, Chandrikha , Dillon, Joseph S. , Hálfdánarson, Þorvarður R. , Cowell, PhD Lindsay G., Else, Tobias , Soares, Heloisa P. , Sukrithan, Vineeth , Geller, David A. , Ramirez, Robert A., Lancaster, William, Chrischilles, Elizabeth A.

Mayo Clinic

Journal of Clinical and Translational Science | February 13, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1017/cts.2026.10703 | PMID 41822553 Get It

Abstract Introduction: Recruitment for rare disease studies is challenging due to small eligible populations. Traditional clinical research management systems often lack tools to track recruitment contacts prior to enrollment. The NET-PRO study, focused on neuroendocrine tumors (NETs), implemented a participation monitoring system to enhance recruitment efficiency and representativeness. Methods: NET-PRO is a multicenter cohort study of 2538 adults diagnosed with gastroenteropancreatic (GEP) or lung NETs between January 2018 and September 2024. Recruitment occurred from January 2022 to February 2025 across 14 U.S. medical centers. Sites used flexible recruitment methods (email, mail, phone, in-clinic) and tracked contacts using REDCap-based tools. Participant characteristics were analyzed by enrollment mode (online or mail) and recruitment difficulty (number of contacts required prior to enrollment) using standardized mean differences, chi-square tests, and ANOVA. Results: Of 9279 contacted patients, 2675 consented (28.8%) and 2538 enrolled (27.4%). Most enrolled online (83.2%), while 16.8% enrolled by mail. Mail respondents were older, had lower education and income, and more comorbidities. Among those enrolled, recruitment difficulty was associated with older age, lower education and income, but not comorbidity. Over half of the most difficult-to-recruit participants enrolled online. Contact methods varied by attempt, with email dominating early contacts and phone/mail used more in later attempts. Conclusions: A participation monitoring tool supported flexible, multimodal recruitment and improved sample representativeness in a rare cancer study. Tracking recruitment contacts enabled adaptive strategies and may reduce bias in observational research by enabling better outreach to harder-to-reach populations.
Artificial intelligence 12-lead electrocardiography to determine atrial fibrillation risk among UK Biobank participants with predisposing conditions
Zheng, Yi , Siontis, Konstantinos C, Attia, Z I, Roten, L, Kazaj, Pooya Mohammadi , Lopez-Jimenez, F, Gersh, Bernard J, Grani, C, Reichlin, Tobias, Friedman, Paul A, Windecker, S, Noseworthy, P A, Siontis, G , López-Jiménez, Francisco , Siontis, George C.M. , Roten, Laurent , Lopez-Jimenez, Francisco , Gräni, Christoph , Reichlin, Tobias , Windecker, Stephan , Noseworthy, Peter A , Siontis, Konstantinos C. , Attia, Zachi I. , Shiri, Isaac , Baj, Giovanni , Gersh, Bernard J. , Friedman, Paul A. , Windecker, Stephan , Noseworthy, Peter A.

Mayo Clinic

European Heart Journal - Digital Health | February 7, 2026 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/ehjdh/ztag025 | PMID 41815107 Get It

Abstract Aims Artificial intelligence electrocardiography (AI-ECG) algorithms are emerging tools for identifying individuals at risk of atrial fibrillation (AF). We evaluated the predictive performance of a validated AI-ECG algorithm for incident AF in UK Biobank participants with AF risk factors, irrespective of prevalent cardiovascular disease, and its incremental value when added to clinical predictors. Methods and results The AI-ECG tool was applied to sinus rhythm ECGs from UK-Biobank participants with risk factors for AF but no AF. Model performance was evaluated using time-dependent ROC-AUC and Harrell’s C-index. Multivariable Cox regression was used to identify clinical risk factors associated with incident AF and to quantify the contribution of AI-ECG. A total of 21 842 participants (56% male) were included. The median follow-up time was 3.7 years (IQR 0.5–5.4) The ECG-AI tool achieved a ROC-AUC of 0.73 (95% CI 0.68–0.78) at 1 and 0.69 (95% CI 0.66–0.72) at 3 years. A multivariable Cox regression model using clinical parameters achieved a ROC-AUC of 0.71 (95% CI 0.66–0.75) at 1 and 0.71 (95% CI 0.68–0.74) at 3 years. By adding ECG-AI to the clinical Cox regression model, the ROC-AUC increased to 0.75 (95%CI 0.71–0.80) at 1 and 0.74 (95% CI 0.71–0.77) at 3 years. AI-ECG showed a hazard ratio of 1.23 per decile increase (95% CI 1.18–1.27). Conclusion An AI-ECG algorithm improved the prediction of incident AF when added to a clinical parameter-based model over a median follow-up time of 3.7 years among individuals with comorbidities predisposing to AF who may benefit from targeted screening and preventive strategies.
Genotype-specific communication profiles in 79,518 individuals with neurodevelopmental disorders
Hsu, Cristiane , Ivaniuk, Alina , Jiménez-Gómez, Andrés , Brünger, Tobias , Perry, M. Scott, Phan, Chiara, Arenivas, Ana, Oyler, Haley O. , Lal, Dennis , Bruenger, Tobias , Bosselmann, Christian , Perry, Michael Scott , Arenivas, Ana , Oyler, Haley O , Leu, Costin , Ivaniuk, Alina , Boßelmann, Christian M. , Ludwig, Natasha N. , Leu, Costin

Mayo Clinic

No container title available | February 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.03.26345484 | PMID 41674637 Get It

Abstract Rationale Neurodevelopmental disorders (NDDs) are characterised by significant challenges in communication, social interaction, and adaptive function, often impacting quality of life. Previous studies support genetic influences on the communication abilities of individuals with NDD, but were either limited to single genetic conditions or to small cohorts with a limited selection of communication measures. Methods We analysed caregiver-reported communication abilities in 79,518 individuals with NDD from the Simons Searchlight and SPARK registries: 4,439 with a CNV-based or monogenic NDD and 75,079 with autism spectrum disorder (ASD) without a known genetic cause (idiopathic ASD) as controls. For analysis, we a priori selected 10 communication-related measures based on their availability in the study cohorts, coverage of distinct communication aspects, and their frequent use in neurodevelopmental phenotyping, yielding 177,328 data points across all study cohorts. The individuals in the Searchlight registry were divided into a Discovery cohort (the 15 most prevalent genetic NDD conditions) and a Confirmation cohort (all other genetic NDD conditions). A second Confirmation cohort was generated using all individuals with genetic ASD forms from the SPARK registry. We then tested each of the three case cohorts and each genetic condition represented in the Discovery cohort against the ASD control cohort. Developmental trajectories were assessed through testing of participants grouped by age at evaluation. Results Measure-level analyses demonstrated significant associations between genetic status and communication abilities, differences in communication abilities between classes of genetic variants (monogenic vs. CNV-based NDDs), and variability between specific genetic NDD conditions. CNV-based NDDs showed milder communication impairment, outperforming idiopathic ASD controls in 9/10 communication measures, whereas monogenic NDD conditions had more pervasive impairments, especially in verbal communication. Although impaired in verbal communication, five monogenic NDD conditions showed at least suggestive strengths in nonverbal and social communication relative to idiopathic ASD controls ( CSNK2A1 , CTNNB1 , SETBP1 , MED13L , and PPP2R5D ), specifically in using gestures. Developmental trajectory analyses revealed STXBP1 as the gene group at highest risk of developmental stagnation in communication abilities. Conclusions These findings underscore the potential of precision speech-language pathology (SLP) approaches tailored to the specific verbal and nonverbal communication strengths and weaknesses of genetic groups. We also provide evidence for measurable improvements and declines in communication abilities with age at the group level, highlighting the need for developmentally informed care. By integrating genetic insights into clinical practice, precision SLP approaches may enhance communication outcomes and developmental progress and improve quality of life for individuals with genetic NDDs.
Adrenal histologic and genetic characteristics of primary aldosteronism in late adulthood
Blinder, Amy, Sapiro, Dina R., Baker, Jessica , Qin, Zhaoping , Bancos, Irina, Lyden, Melanie L. , Young, W F, Wachtel, Heather , Cohen, D., Kürzinger, Lydia, Fassnacht, Martin, Reincke, Martin, Else, Tobias , Rainey, W E, Nanba, Kazutaka , Bancos, Irina , Fassnacht, Martin , Williams, Tracy Ann , Reincke, Martin , Else, Tobias , Udager, Aaron M , Nanba, Kazutaka , Bancos, Irina , Cohen, Debbie L. , Faßnacht, Martin , Luther, James Matthew , Williams, Tracy Ann , Reincke, Martín , Turcu, Adina F. , Giordano, Thomas J.

Mayo Clinic

European Journal of Endocrinology | January 27, 2026 | Volume: 194 | Issue: 2 | Pages: 208-216

10.1093/ejendo/lvag022 | PMID 41618603 Get It

Abstract Objective Recent studies suggest a unique disease profile in elderly patients with primary aldosteronism (PA), who have a high prevalence of comorbidities and low clinical cure rate post-adrenalectomy. This study aims to investigate histopathology and genetic characteristics of PA in late adulthood. Methods Formalin-fixed, paraffin-embedded adrenal tissue sections from 114 patients with PA who underwent unilateral adrenalectomy at age 60 or older were used. Aldosterone synthase (CYP11B2) immunohistochemistry (IHC) was performed for histopathologic analysis. Somatic DNA variants were identified in aldosterone-producing tissue following CYP11B2 IHC-guided sequencing. Results Histopathologic analysis revealed that 56 adrenals contained an aldosterone-producing nodule (APN) (49%), 44 contained an aldosterone-producing adenoma (APA) (39%), 7 contained multiple APN (6%), and 7 contained only non-functioning adenomas [NFA, of which 6 had at least one aldosterone-producing micronodule (APM) in the adjacent tissue] (6%). NFAs were also identified alongside APN/APA in 24 cases. An APN was the most common histologic subtype in men (51/88, 58%), while APA was predominant in women (18/26, 69%). Of 67 APNs with successful sequencing, the majority had variants in CACNA1D (40/67, 60%). KCNJ5 variants were the most common alteration in APA (14/44, 32%). Conclusions Older individuals with lateralized PA exhibit distinct genetic and histologic causes of disease with sex differences in mutation prevalence and adrenal histopathology. In APN, the most frequently altered gene is CACNA1D, while KCNJ5 variants are most common in APA. Unlike young patients with PA, the presence of NFA is a frequent observation in late adulthood individuals with PA.
Epilepsy disease classification: a community effort to enhance the Mondo Disease Ontology
Vasilevsky, Nicole, Gehrke, Sarah , Mullen, Kathleen , Barua, Subit , Braun, Ian , Brünger, Tobias , Ivaniuk, Alina, Korn, Daniel, Lal, Dennis , Marsh, Stephanie, O’Loughlin, Elaine, Olson, Daniel, Shwetar, Yousif, Vanessa, Vogel-Farley, Grabenstatter, Heidi L. , Haendel, Melissa, Mungall, Christopher, Toro, Sabrina, Vasilevsky, Nicole A , Korn, Daniel , Lal, Dennis , Haendel, Melissa , Mungall, Christopher J , Coughlin, Curtis R. , Ivaniuk, Alina , O'Loughlin, Elaine K. , Olson, Daniel , Shwetar, Yousif J. , Sofocleous, Christalena , Vogel‐Farley, Vanessa K. , Haendel, Melissa , Toro, Sabrina

Mayo Clinic

Database | January 14, 2026 | Volume: 2026 | Issue: No issue available | Pages: No page available

10.1093/database/baag004 | PMID 41697974 Get It

Abstract Motivation: Epilepsy is a diverse group of neurological disorders affecting over 50 million people worldwide. While common epilepsy types are well studied, rare epilepsies—often severe and genetically complex—pose significant challenges in diagnosis, research, and treatment. Accurate and interoperable etiology and disease classifications are critical for improving data sharing, supporting clinical decision-making, and advancing rare disease research. Results: To enhance the accuracy of epilepsy-related disease concept representation within the Mondo Disease Ontology (Mondo), we conducted a series of expert-driven workshops in collaboration with the team from the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). Specialists in epileptology, genetics, neurodevelopment, biomedical ontology, and patient community advocates systematically reviewed and revised the epilepsy hierarchy in Mondo, aligning it with the International League Against Epilepsy (ILAE) classification system. These updates include reclassification of epilepsy subtypes, including syndromes, age-related epilepsies, and developmental epileptic encephalopathies, resulting in a more granular, standardized, and clinically relevant structure. Mondo now offers an enhanced framework for integrating epilepsy data across resources, enabling improved interoperability and facilitating rare disease research and data curation, with continued efforts underway to further refine and expand this integration.
Balancing blood pressure and catecholamine support is critical in heart failure-related cardiogenic shock patients
Beer, Benedikt N. , Kellner, Caroline , Sundermeyer, Jonas , Besch, Lisa, Dettling, Angela , Kriz, Marvin , Kirchhof, Paulus , Blankenberg, S, MORICI, Nuccia, Proudfoot, Alastair, Schwinger, Robert H. G., Pauschinger, Matthias , Skurk, Carsten, Jung, Christian, Thiele, Holger, Skurk, Carsten , Jung, Christian , Blankenberg, Stefan , Scherer, Clemens , Mangner, Norman , Proudfoot, Alastair G , Graf, Tobias , Jung, Christian , Thiele, Holger , Schrage, Benedikt , Kirchhof, Paulus , Blankenberg, Stefan , Bertoldi, Letizia Fausta , Lüsebrink, Enzo , Scherer, Clemens , Morici, Nuccia , Proudfoot, Alastair , Schwinger, Robert H. G., Kanwar, Manreet , Jentzer, Jacob C. , Thiele, Hölger , Schrage, Benedikt

Mayo Clinic

European Journal of Heart Failure | January 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag009 | PMID 41771117 Get It

Abstract Aims Cardiogenic shock (CS) is often treated with catecholamines titrated to an adequate target mean arterial pressure (MAP) while minimizing adverse effects. We aim to assess the optimal catecholamine dose/MAP balance in heart failure-associated CS (HF-CS). Methods Patients with HF-CS were retrospectively enrolled from 16 tertiary centres in 5 European countries (2016–2021; NCT03313687). Dosage was quantified by inotropic scores (epinephrine, norepinephrine, and dobutamine). Associations of baseline and seven-day summarized dosage with intensive care unit (ICU) discharge (mixed-effects logistic regression) and 30-day mortality (Cox regression) were analysed. Potential catecholamine/MAP target ratios for optimized outcomes were assessed in models adjusted for age, sex, pH, lactate and prior resuscitation, stratified by centre. Results N = 704 patients: median age 63 years, 74% male, 34% post-resuscitation, median lactate 5.2 mmol/l. Of these, 53% were discharged from ICU, 48% died within 30 days. Higher inotropic scores independently predicted a lower probability of ICU discharge (baseline score: OR 0.78 [95%-CI 0.69–0.88]; summarized score: OR 0.46 [0.38–0.56]; both P < .001) and higher risk of 30-day mortality (baseline score: HR 1.27 [1.15–1.40], summarized score HR 1.83 [1.60–2.09]; both P < .001). A score/MAP ratio <0.403 µg/kg/min/mmHg was associated with higher ICU discharge odds (ceiling effect); a < 0.426 µg/kg/min/mmHg with lower 30-day mortality hazards (no ceiling effect). Lowering catecholamine doses by accepting reduced MAP targets was linked to better outcomes. Conclusion In HF-CS, higher catecholamine support independently associates with worse outcomes. Accepting lower blood pressure targets to reduce catecholamine dosage may improve outcomes. Validation in randomized controlled trials is urgently needed.